|
1
|
Ben-Porath I and Benvenisty N:
Characterization of a tumor-associated gene, a member of a novel
family of genes encoding membrane glycoproteins. Gene. 183:69–75.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fumoto S, Hiyama K, Tanimoto K, Noguchi T,
Hihara J, Hiyama E, Noguchi T and Nishiyama M: EMP3 as a tumor
suppressor gene for esophageal squamous cell carcinoma. Cancer
Lett. 274:25–32. 2009. View Article : Google Scholar
|
|
3
|
Alaminos M, Dávalos V, Ropero S, Setién F,
Paz MF, Herranz M, Fraga MF, Mora J, Cheung NKV, Gerald WL and
Esteller M: EMP3, a myelin-related gene located in the critical
19q13.3 region, is epigenetically silenced and exhibits features of
a candidate tumor suppressor in glioma and neuroblastoma. Cancer
Res. 65:2565–2571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xue Q, Zhou Y, Wan C, Lv L, Chen B, Cao X,
Ju G, Huang Y, Ni R and Mao G: Epithelial membrane protein 3 is
frequently shown as promoter methylation and functions as a tumor
suppressor gene in non-small cell lung cancer. Exp Mol Pathol.
95:313–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jun F, Hong J, Liu Q, Guo Y, Liao Y, Huang
J, Wen S and Shen L: Epithelial membrane protein 3 regulates TGF-β
signaling activation in CD44-high glioblastoma. Oncotarget.
8:14343–14358. 2017. View Article : Google Scholar
|
|
6
|
Hsieh YH, Hsieh SC, Lee CH, Yang SF, Cheng
CW, Tang MJ, Lin CL, Lin CL and Chou RH: Targeting EMP3 suppresses
proliferation and invasion of hepatocellular carcinoma cells
through inactivation of PI3K/Akt pathway. Oncotarget.
6:34859–34874. 2015. View Article : Google Scholar
|
|
7
|
Hong XC, Fen YJ, Yan GC, Hong H, Yan CH,
Bing LW and Zhong YH: Epithelial membrane protein 3 functions as an
oncogene and is regulated by microRNA-765 in primary breast
carcinoma. Mol Med Rep. 12:6445–6450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ernst A, Hofmann S, Ahmadi R, Becker N,
Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H,
et al: Genomic and expression profiling of glioblastoma stem
cell-like spheroid cultures identifies novel tumor-relevant genes
associated with survival. Clin Cancer Res. 21:6541–6550. 2009.
View Article : Google Scholar
|
|
9
|
Li JJ, Li R, Wang W, Zhang B, Song X,
Zhang C, Gao Y, Liao Q, He Y, You S, et al: IDH2 is a novel
diagnostic and prognostic serum biomarker for non-small-cell lung
cancer. Mol Oncol. 12:602–610. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alidousty C, Baar T, Heydt C,
Wagener-Ryczek S, Kron A, Wolf J, Buettner R and Schultheis AM:
Advance of theragnosis biomarkers in lung cancer: From clinical to
molecular pathology and biology. J Thorac Dis. 11(Suppl 1): S3–S8.
2019. View Article : Google Scholar :
|
|
11
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar :
|
|
12
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.
|
|
13
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen SY, Huang YC, Liu SP, Tsai FJ, Shyu
WC and Lin SZ: An overview of concepts for cancer stem cells. Cell
Transplant. 20:113–120. 2011. View Article : Google Scholar
|
|
15
|
Rycaj K and Tang DG: Cancer stem cells and
radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suresh R, Ali S, Ahmad A, Philip PA and
Sarkar FH: The role of cancer stem cells in recurrent and
drug-resistant lung cancer. Adv Exp Med Biol. 890:57–74. 2016.
View Article : Google Scholar
|
|
17
|
Zhao W, Luo Y, Li B and Zhang T:
Tumorigenic lung tumorospheres exhibit stem-like features with
significantly increased expression of CD133 and ABCG2. Mol Med Rep.
14:2598–2606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okudela K, Woo T, Mitsui H, Tajiri M,
Masuda M and Ohashi K: Expression of the potential cancer stem cell
markers, CD133, CD44, ALDH1, and β-catenin, in primary lung
adenocarcinoma-their prognostic significance. Pathol Int.
62:762–801. 2012. View Article : Google Scholar
|
|
19
|
Marcato P, Dean CA, Pan D, Araslanova R,
Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al:
Aldehyde dehydrogenase activity of breast cancer stem cells is
primarily due to isoform ALDH1A3 and its expression is predictive
of metastasis. Stem Cells. 29:32–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu SL, Liu S, Cui W, Shi Y, Liu Q, Duan
JJ, Yu SC, Zhang X, Cui YH, Kung HF and Bian XW: Aldehyde
dehydrogenase 1A1 circumscribes high invasive glioma cells and
predicts poor prognosis. Am J Cancer Res. 5:1471–1483. 2015.
|
|
21
|
Vishnubalaji R, Manikandan M, Fahad M,
Hamam R, Alfayez M, Kassem M, Aldahmash A and Alajez NM: Molecular
profiling of ALDH1+ colorectal cancer stem cells reveals
preferential activation of MAPK, FAK, and oxidative stress
pro-survival signalling pathways. Oncotarget. 9:13551–13564. 2018.
View Article : Google Scholar
|
|
22
|
Kim IG, Kim SY, Choi SI, Lee JH, Kim KC
and Cho EW: Fibulin-3-mediated inhibition of
epithelial-to-mesenchymal transition and self-renewal of
ALDH+ lung cancer stem cells through IGF1R signaling.
Oncogene. 33:3908–3917. 2014. View Article : Google Scholar
|
|
23
|
Buck E, Eyzaguirre A, Barr S, Thompson S,
Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P and Haley JD:
Loss of homotypic cell adhesion by epithelial-mesenchymal
transition or mutation limits sensitivity to epidermal growth
factor receptor inhibition. Mol Cancer Ther. 6:532–541. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Creighton CJ, Li X, Landis M, Dixon JM,
Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A,
Herschkowitz JI, et al: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Du S, Bouquet S, Lo CH, Pellicciotta I,
Bolourchi S, Parry R and Barcellos-Hoff MH: Attenuation of the DNA
damage response by transforming growth factor-beta inhibitors
enhances radiation sensitivity of non-small-cell lung cancer cells
in vitro and in vivo. Int J Radiat Oncol Biol Phys. 91:91–99. 2015.
View Article : Google Scholar
|
|
27
|
Murai F, Koinuma D, Shinozaki-Ushiku A,
Fukayama M, Miyaozono K and Ehata S: EZH2 promotes progression of
small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway.
Cell Discov. 1:150262015. View Article : Google Scholar
|
|
28
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao Y, Baker D and Dijke PT:
TGF-β-mediated epithelial-mesenchymal transition and cancer
metastasis. Int J Mol Sci. 20:27672019. View Article : Google Scholar
|
|
30
|
Wang Y and Shang Y: Epigenetic control of
epithelial-to-mesenchymal transition and cancer metastasis. Exp
Cell Res. 319:160–169. 2013. View Article : Google Scholar
|
|
31
|
Palma Cde S, Grassi ML, Thomé CH, Ferreira
GA, Albuquerque D, Pinto MT, Melo FU, Kashima S, Covas DT, Pitteri
SJ and Faça VM: Proteomic analysis of epithelial to mesenchymal
transition (EMT) reveals cross-talk between SNAIL and HDAC1
proteins in breast cancer cells. Mol Cell Proteomics. 15:906–917.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar
|
|
33
|
Choi SI, Lee JH, Kim RK, Jung U, Kahm YJ,
Cho EW and Kim IG: HSPA1L enhances cancer stem cell-like properties
by activating IGF1Rβ and regulating β-catenin transcription. Int J
Mol Sci. 21:69572020. View Article : Google Scholar
|
|
34
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar
|
|
36
|
Ma Y, Schröder DC, Nenkov M, Rizwan MN,
Abubrig M, Sonnemann J, Murrieta-Coxca JM, Morales-Prieto DM,
Westermann M, Gassler N and Chen Y: Epithelial membrane protein 2
suppresses non-small cell lung cancer cell growth by inhibition of
MAPK pathway. Int J Mol Sci. 22:29442021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar
|
|
38
|
de Caestecker MP, Piek E and Roberts AB:
Role of transforming growth factor-beta signaling in cancer. J Natl
Cancer Inst. 92:1388–1402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshinaga K, Obata H, Jurukovski V,
Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P,
Todorovic V, et al: Perturbation of transforming growth factor
(TGF)-beta1 association with latent TGF-beta binding protein yields
inflammation and tumors. Proc Natl Acad Sci USA. 105:18758–18763.
2008. View Article : Google Scholar
|
|
40
|
Korkaya H, Liu S and Wicha MS: Regulation
of cancer stem cells by cytokine networks: Attacking cancer's
inflammatory roots. Clin Cancer Res. 17:6125–6129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou C, Liu J, Tang Y and Liang X:
Inflammation linking EMT and cancer stem cells. Oral Oncol.
48:1068–1075. 2012. View Article : Google Scholar
|
|
42
|
Christians A, Poisel E, Hartmann C,
Deimling AV and Pusch S: Characterization of the epithelial
membrane protein 3 interaction network reveals a potential
functional link to mitogenic signal transduction regulation. Int J
Cancer. 145:461–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang YW, Li WM, Wu WJ, Chai CY, Liu HS,
Lai MD and Chow NH: Potential significance of EMP3 in patients with
upper urinary tract urothelial carcinoma: Crosstalk with
ErbB2-PI3K-Akt pathway. J Urol. 192:242–251. 2014. View Article : Google Scholar
|
|
44
|
Lin CY, Lee CH, Chuang YH, Lee JY, Chiu
YY, Lee YH, Jong YJ, Hwang JK, Huang SH, Chen LC, et al: Membrane
protein-regulated networks across human cancers. Nat Commun.
10:31312019. View Article : Google Scholar :
|
|
45
|
Pasto A, Giordano F, Evangelopoulos M,
Amadori A and Tasiotti E: Cell membrane protein functionalization
of nanoparticles as a new tumor-targeting strategy. Clin Transl
Med. 8:82019. View Article : Google Scholar :
|
|
46
|
Schmit K and Michiels C: TMEM proteins in
cancer: A review. Front Pharmacol. 9:13452018. View Article : Google Scholar :
|
